Scientists at the University of Oxford, led by Professor Ahmed Ahmed, are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.
In this study, the CRUK-funded researchers will establish the targets for the vaccine. They will find out which proteins on the surface of early-stage ovarian cancer cells are most strongly recognised by the immune system and how effectively the vaccine kills mini-models of ovarian cancer called organoids.
If this research is successful, work will then begin on clinical trials of the vaccine. The hope is that in the future, women could be offered this vaccine to prevent ovarian cancer in the first place.
Read the full story on the MRC Weatherall Institute of Molecular Medicine (MRC WIMM) website.
more recommended stories
Psychedelic Use Linked to Major Life Changes StudyQuick Summary 83% of users reported.
Brain Categorization Redefined by New Neuroscience StudyKey Highlights Brain Categorization is not.
One Health Summit: WHO Leads Global Health ResponseKey Highlights Global leaders convened in.
Prenatal Smoking Raises Risk of Child Mental DisordersKey Summary Prenatal smoking is associated.
Physical Activity Guidelines Gap: Walking is InsufficientQuick Summary Walking remains the most.
Breast Cancer Risk Rises with Aging Tissue ChangesKey Highlights A 3-million-cell atlas reveals.
Type 2 Diabetes Risk Rising in Genetically SusceptibleQuick Summary Rising type 2 diabetes.
Female Microbiome Shaped by Diet, Stress, Unhealthy LifestyleQuick Summary Lifestyle factors significantly influence.
Transcatheter Valve-in-Valve Improves Mitral OutcomesKey Highlights Transcatheter mitral valve-in-valve (mVIV).
Stroke Rehabilitation: Early High-Intensity Therapy FindingsKey Highlights High-intensity therapy within 2.
Leave a Comment